Pivotal Bioventure Partners Investment Advisor 13F annual report

Pivotal Bioventure Partners Investment Advisor is an investment fund managing more than $130 billion ran by Robert Hopfner. There are currently 10 companies in Mr. Hopfner’s portfolio. The largest investments include Vaxcyte and Inozyme Pharma, together worth $79.9 billion.

$130 billion Assets Under Management (AUM)

As of 6th August 2024, Pivotal Bioventure Partners Investment Advisor’s top holding is 793,036 shares of Vaxcyte currently worth over $59.9 billion and making up 46.0% of the portfolio value. Relative to the number of outstanding shares of Vaxcyte, Pivotal Bioventure Partners Investment Advisor owns more than approximately 0.1% of the company. In addition, the fund holds 4,494,851 shares of Inozyme Pharma worth $20 billion, whose value fell 4.3% in the past six months. The third-largest holding is Oculis Holding Ag worth $19.1 billion and the next is Arcutis Biotherapeutics Inc worth $19 billion, with 2,041,108 shares owned.

Currently, Pivotal Bioventure Partners Investment Advisor's portfolio is worth at least $130 billion. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Pivotal Bioventure Partners Investment Advisor

The Pivotal Bioventure Partners Investment Advisor office and employees reside in San Francisco, California. According to the last 13-F report filed with the SEC, Robert Hopfner serves as the Managing Partner at Pivotal Bioventure Partners Investment Advisor.

Recent trades

In the most recent 13F filing, Pivotal Bioventure Partners Investment Advisor revealed that it had opened a new position in Oculis Holding Ag and bought 1,595,918 shares worth $19.1 billion.

The investment fund also strengthened its position in Vaxcyte by buying 16,997 additional shares. This makes their stake in Vaxcyte total 793,036 shares worth $59.9 billion. Vaxcyte dropped approximately 0.1% in the past year.

On the other hand, there are companies that Pivotal Bioventure Partners Investment Advisor is getting rid of from its portfolio. Pivotal Bioventure Partners Investment Advisor closed its position in Karuna Therapeutics Inc on 13th August 2024. It sold the previously owned 765,895 shares for $172 million. Robert Hopfner also disclosed a decreased stake in Exscientia Plc by approximately 0.1%. This leaves the value of the investment at $3.93 billion and 770,500 shares.

One of the smallest hedge funds

The two most similar investment funds to Pivotal Bioventure Partners Investment Advisor are Triton Wealth Management, P and Brown Advisory. They manage $130 billion and $130 billion respectively.

Robert Hopfner investment strategy

Pivotal Bioventure Partners Investment Advisor’s portfolio is diversified across 2 sectors. Currently, their heaviest sector is Health Care — making up 76.2% of the total portfolio value. The fund focuses on investments in the United States as 40.0% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are small-cap stocks. Stocks with a size of more than $100 million in market cap make up 20% of the total holdings value. On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio. The average market cap of the portfolio companies is close to $1.13 billion.

The complete list of Pivotal Bioventure Partners Investment Advisor trades based on 13F SEC filings

These positions were updated on August 13th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security	Shares Owned	Value	Allocation
Vaxcyte, Inc.	2.19% 793,036	$59,882,148,000	46.04%
Inozyme Pharma, Inc.	68.91% 4,494,851	$20,047,035,000	15.41%
Oculis Holding Ag	Opened 1,595,918	$19,071,220,000	14.66%
Arcutis Biotherapeutics Inc	258.69% 2,041,108	$18,982,304,000	14.59%
Exscientia Plc	0.23% 770,500	$3,929,550,000	3.02%
Rallybio Corp	5.87% 2,404,644	$3,222,223,000	2.48%
Vigil Neuroscience Inc	No change 560,595	$2,242,380,000	1.72%
Bolt Biotherapeutics Inc	No change 1,891,467	$1,418,600,000	1.09%
Io Biotech Inc	Opened 864,197	$1,011,110,000	0.78%
Aligos Therapeutics, Inc.	No change 743,215	$260,125,000	0.20%
Karuna Therapeutics Inc	Closed 765,895	$172,273,000
Akouos, Inc.	Closed 1,794,088	$12,128,000
Fusion Pharmaceuticals Inc.	Closed 1,560,984	$4,699,000
No transactions found
Showing first 500 out of 13 holdings